Wegovy 1,7 Mg

Clinical Monograph: Wegovy 1.7 mg (Semaglutide)

Wegovy 1.7 mg pre-filled injection packaging. Source: Buy Super Specialty Medicines for Cancer, HIV & Kidney Care at …

1. Classification and Chemical Overview

Semaglutide is a recombinant human GLP-1 analogue engineered via recombinant DNA technology in Saccharomyces cerevisiae. Structurally, it maintains 94% amino acid sequence homology with native human GLP-1 (7-37). Specific molecular modifications include an amino acid substitution at position 8 (alanine to $\alpha$-aminobutyric acid) to prevent enzymatic inactivation by dipeptidyl peptidase-4 (DPP-4), alongside a C18 fatty diacid side-chain attached at position 26 (lysine) that promotes high-affinity albumin binding and delays renal clearance.

Under the Anatomical Therapeutic Chemical (ATC) system, semaglutide is categorized under A10BJ06. Wegovy is classified internationally as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

Semaglutide binds to central and peripheral GLP-1 receptors, engaging neuroendocrine pathways that regulate satiety, energy intake, and systemic metabolic function:

• Central Satiety Signal Activation: Crosses key blood-brain barrier structures (e.g., area postrema, arcuate nucleus of the hypothalamus) to activate anorexigenic pro-opiomelanocortin (POMC) neurons while inhibiting orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways, resulting in suppressed appetite and reduced cravings.

• Gastric Emptying Delay: Slows initial postprandial gastric motility, extending intragastric retention of nutrients and enhancing post-meal fullness.

• Glycemic & Cardiovascular Effects: Enhances glucose-dependent insulin secretion, suppresses postprandial glucagon secretion, improves insulin sensitivity secondary to weight loss, and demonstrates anti-atherosclerotic effects across the vascular endothelium.

3. Approved Clinical Indications and Dosing Scope

Licensing for Wegovy 1.7 mg includes:

• Chronic Weight Management: Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:

  • An initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity), or

  • An initial BMI of ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea).

• Pediatric Weight Management: Indicated in pediatric patients aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex (obesity).

• Cardiovascular Risk Reduction: Reduction of the risk of major adverse cardiovascular events (MACE; cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight.

Dosing & Escalation Schedule:

• Stepwise Escalation Position: Wegovy treatment MUST follow a strict 16-week titration schedule (0.25 mg, 0.5 mg, 1.0 mg monthly steps) before advancing to 1.7 mg once weekly at Month 4 (Weeks 13–16).

• Maintenance Option: Patients may remain on 1.7 mg once weekly as their target long-term maintenance dose, or further escalate to the maximum dosage of 2.4 mg once weekly after 4 weeks if additional weight loss is required and tolerated.

• Administration: Injected subcutaneously once weekly into the abdomen, thigh, or upper arm on the same day each week, regardless of meals.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Absolute bioavailability is approximately 89%. Peak plasma exposure (Cmax​) occurs 1 to 3 days (Tmax​) post-injection. Steady-state plasma concentrations are achieved following 4 to 5 weeks of consistent once-weekly administration.

• Distribution: Extensively bound to plasma proteins (> 99%, primarily albumin). Volume of distribution (Vd​) is approximately 12.5 L.

• Biotransformation: Primary degradation occurs through proteolytic cleavage of the peptide backbone paired with sequential $\beta$-oxidation of the fatty acid side-chain. It does not rely on hepatic Cytochrome P450 pathways for clearance.

• Elimination: Clearance occurs via urine and feces as conjugated or degraded metabolites. The elimination half-life (t1/2​) is approximately 1 week (7 days).

5. Physiological Effects and Adverse Event Spectrum

Semaglutide delays gastrointestinal transit, alters central food preference behavior, and impacts systemic fluid levels through reduced calorie intake.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue/asthenia.

• Common ($\ge 1/100$ to $<1/10$): Dyspepsia, gastroesophageal reflux disease (GERD), eructation, flatulence, abdominal distension, gastritis, dizziness, hypoglycemia (in patients with type 2 diabetes taking secretagogues/insulin), cholelithiasis, hair loss (alopecia), injection site reactions.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Acute pancreatitis, cholecystitis, elevated resting heart rate, acute kidney injury, dysgeusia, delayed gastric emptying.

• Rare (<1/1,000): Anaphylactic reactions, angioedema.

6. Contraindications, Drug Interactions, and Clinical Precautions

Kontraindikationen

• Personal or family history of Medullary Thyroid Carcinoma (MTC).

• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Known hypersensitivity to semaglutide or formulation excipients.

• Pregnancy (must be discontinued at least 2 months prior to a planned pregnancy due to potential fetal harm).

Key Drug Interactions

• Oral Medication Absorption: Delayed gastric emptying can alter the absorption velocity and maximum concentrations (Cmax​) of concomitantly administered oral medications.

• Hypoglycemia with Concomitant Antidiabetics: Increased risk of hypoglycemia when combined with insulin secretagogues (e.g., sulfonylureas) or exogenous insulin; dosage adjustments of secretagogues may be required.

Clinical Precautions and Monitoring

• Boxed Warning (Thyroid C-Cell Tumors): Causes dose- and duration-dependent thyroid C-cell tumors in rodents. Advise patients regarding thyroid tumor symptoms (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness).

• Acute Pancreatitis: Discontinue immediately if persistent, severe abdominal pain radiating to the back is observed.

• Gallbladder Disease: Rapid weight loss increases the risk of cholelithiasis and cholecystitis; evaluate patients if gallstone symptoms occur.

• Acute Renal Impairment: Dehydration caused by severe gastrointestinal adverse reactions (vomiting, diarrhea) can precipitate acute renal failure. Fluid volume status must be adequately maintained.

• Suicidal Ideation & Behavior: Monitor for emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behavior.